Influenza Vaccine Market 2018

More Details @ http://www.dpiresearch.com/report-details.php?P_ID=89

Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants.
The United States seasonal influenza vaccine market is the most attractive of those covered in the report. The United States market for seasonal influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. United Kingdom will be the second–largest market for seasonal influenza vaccine which is expected to grow at a CAGR of XX% by 2022. Germany is expected to be third largest seasonal influenza vaccine market being followed by Japan by the end of the forecasted period.
Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market.
Seven Major Markets(7MM) covered in the report are as follows:
1. United States
2. United Kingdom
3. France
4. Italy
5. Spain
6. Germany
7. Japan
Major and Promising Vaccines covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4. Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8. FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Seasonal Influenza Vaccine Report is segmented with 10 Chapters:
Chapter 1: Chapter one is the introduction with Executive Summary
Chapter 2: Chapter two provides overall recent and forecasts data for the seasonal influenza vaccine market in the top seven countries. This Chapter divided into 4 parts
1. Overall seasonal influenza vaccine market data from 2010 to 2022
2. Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022
3. Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022
4. Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022
Chapter 3: Key market drivers and barriers in the seasonal influenza vaccine market.
Chapter 4: Chapter four gives detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage.
Chapter 5: Chapter five gives detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination.
Chapter 6: Chapter six offers information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan.
Chapter 7: Chapter seven highlights key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals.
Chapter 8: Chapter eight provides detailed pipeline influenza vaccines in various companies’ pipelines with clinical development and early stage development vaccines.
Chapter 9: Chapter nine offers detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase.
Chapter 10: Chapter ten gives information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine.

Non Invasive Prenatal Testing Market and Forecast to 2021

Market growth can be attributed to factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). With increased patient access to NIPT test, the NIPT market is anticipated to have a positive outlook in the coming years. High test cost, strict regulatory requirements and ethical hurdles is restraining the growth of NIPT test market.

 

Browse full table of contents and data tables at : http://www.dpiresearch.com/report-details.php?P_ID=76

 

United States is seen as the dominant player in the NIPT test market followed by Germany, China and India in 2015. In the coming years, NIPT test market is expected to witness the highest growth rate in the Asian region, with emphasis on China and India. These countries are expected to increase revenues for the manufacturers of tests involved in NIPT test market.

On the basis of test, MaterniT21 plus test has gain its momentum in 2011 when there was only one NIPT test available in the market. MaterniT21 test market revenue value was US$ XX Million in 2015. It is expected that MaterniT21 plus test will lead the NIPT test market with the market share of more than XX% by the year 2021. Other NIPT tests such as Panorama, Harmony, Verifi, NIFTY and Prerna test have emerged as the promising test in the NIPT test market. The major companies are expanding their tests through collaboration, distribution agreement, strategic alliances and partnerships with clinical laboratories and hospitals.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, country wise actual and potential market, NIPT test analysis with volume and market revenue and competitive landscape. The report also covers market growth drivers, challenges, current and upcoming trends of the NIPT test market

GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET SEGMENTATION

Global Non-Invasive Prenatal Testing (NIPT) Market – By Test Type

1.    MaterniT21 PLUS

2.    Harmony

3.    NIFTY

4.    Verifi

5.    Panorama

6.    PrenaTest

7.    BambniTest

8.    informaSeq

9.    VisibiliT

10.  Veracity

11.  IONA Test

Global Non-Invasive Prenatal Testing (NIPT) Market – By Country

1.    United States

2.    United Kingdom

3.    Germany

4.    Italy

5.    Spain

6.    France

7.    Switzerland

8.    Sweden

9.    Belgium

10.  Australia

11.  New Zealand

12.  Japan

13.  China

14.  India

15.Brazil

Kidney Transplant Market Research Report Analysis

Kidney transplant is the most commonly conducted transplant surgery worldwide. It has gained widespread popularity by improving the outcome of end-stage renal disease (ESRD) patients. With advances in kidney transplant methods and improvement in transplant success, a kidney transplant is now widely considered to be the best way of treating chronic kidney disease for many people. As the number of organ donors is increasing, an increase in transplant procedures is bound to happen. However, due to costlier procedure the market shift is expected to occur in Asian countries where medical tourism is being promoted.

Browse full table of contents and data tables at : http://www.dpiresearch.com/report-details.php?P_ID=75

Kidney Transplant Performed Analysis: United States is the leading kidney transplant performed with more than 40% share in 2015. The number of Kidney transplant done in 10 countries covered in the report was more than 40 Thousand in 2015. Brazil is the second leading kidney transplant performed country with more than 10% share.United Kingdom stands at the 3rd position in kidney transplant number. France and Mexico stand at the 4th and 5th place respectively in 2015.

Kidney Transplant Market Analysis: United States is the leading market for kidney transplant in 10 countries covered being followed by France.  Spain stands at the 3rd position followed by Germany. Japan and Italy are competing very closely with each other to capture the maximum market share.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides the number of kidney transplant, as well as market and market shares of Kidney Transplant market. The report entails major organ transplant (immunosuppressant) drug sales analysis. This report also covers key development, drivers and challenges of Kidney Transplant market.

The 10 countries covered in the report are analysed from two viewpoints:

1. Number of Kidney Transplant Performed (2008 – 2021)

2. Kidney Transplant Market (2008 – 2021)

Based on geographical distribution, the Kidney Transplant market is categorized into following sub-markets:

1.    United States

2.    Germany

3.    France

4.    Italy

5.    United Kingdom

6.    Japan

7.    Argentina

8.    Mexico

9.    Spain

10.  Brazil